Обоснование критериев оценки биологической активности минеральных вод

Автори під час проведення порівняльного аналізу біологічної дії борвміщуючих мінеральних вод різної мінералізації виявила якісну та кількісну однаковість їх впливу. Інтегративні показники властивостей мінеральних вод, що використовуються на сьогоднішній день, не пояснюють виявлені особливості дії. Автори роблять висновок, що застосування відносних показників властивостей мінеральних вод, прив’язаних до 1 граму мінеральних речовин, які містяться у воді, дозволить більш точно оцінювати властивості мінеральних вод.Authors, carrying out the comparative analysis of biological action of the boron containing mineral waters of a different mineralization, have found out qualitative and quantitative similarity of their influence. Used for today integrate indicators of properties of mineral waters do not explain the taped features of action. Authors come to conclusion that transition to relative indicators of properties of the mineral waters, adhered to 1 gram of the mineral substances containing in water, allows to estimate properties of mineral waters more precisely

Квадратура в стінопису XVIII століття у Східній Галичині на тлі західноєвропейського мистецтва бароко

Background : Systemic hypertension and proteinuria are frequent complications in dogs with Cushing's syndrome and do not always resolve after treatment of hypercortisolism. Therefore, dogs with Cushing's syndrome may be at risk for renal dysfunction before and after treatment. Hypothesis/Objectives : To assess renal function in dogs with ACTH-dependent hyperadrenocorticism (ADHAC) before and after treatment. Animals : A total of 19 dogs with ADHAC and 12 control dogs. Methods : Renal function was assessed before and at 1, 3, 6, and 12 similar to months after treatment. Twelve dogs were treated with trilostane and 7 dogs by transsphenoidal hypophysectomy. Routine renal markers were measured and urinary albumin (uALB), immunoglobulin G (uIgG), and retinol-binding protein (uRBP) were assessed by ELISA. Urinary N-acetyl-beta-D-glucosaminidase (uNAG) was determined colorimetrically. All urinary markers were indexed to urinary creatinine concentration (c). Plasma clearance of creatinine (Clcreat), exo-iohexol (Clexo), and endo-iohexol (Clendo) was used to measure glomerular filtration rate (GFR). Data were analyzed using a general linear model. Results : Serum creatinine and urea concentrations increased post-treatment, but remained within reference ranges. Plasma Clcreat and Clendo were significantly lower post-treatment, whereas Clexo was not different. Urinary protein-to-creatinine ratio (UPC), uALB/c, uIgG/c, and uRBP/c were decreased post-treatment, but at 12 similar to months 5/13 dogs remained proteinuric. Urinary NAG/c did not change significantly. Conclusions and clinical importance : A decrease in GFR and persistent proteinuria post-treatment may warrant the clinician's attention. Future research including renal histopathology of dogs with persistent proteinuria or low GFR is needed to further assess renal outcome

Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety

<p>Abstract</p> <p>Object</p> <p>To assess the effects of radiosurgery (RS) on the radiological and hormonal control and its toxicity in the treatment of pituitary adenomas.</p> <p>Methods</p> <p>Retrospective analysis of 42 patients out of the first 48 consecutive patients with pituitary adenomas treated with RS between 1999 and 2008 with a 6 months minimum follow-up. RS was delivered with Gamma Knife as a primary or adjuvant treatment. There were 14 patients with non-secretory adenomas and, among functioning adenomas, 9 were prolactinomas, 9 were adrenocorticotropic hormone-secreting and 10 were growth hormone-secreting tumors. Hormonal control was defined as hormonal response (decline of more than 50% from the pre-RS levels) and hormonal normalization. Radiological control was defined as stasis or shrinkage of the tumor. Hypopituitarism and visual deficit were the morbidity outcomes. Hypopituitarism was defined as the initiation of any hormone replacement therapy and visual deficit as loss of visual acuity or visual field after RS.</p> <p>Results</p> <p>The median follow-up was 42 months (6-109 months). The median dose was 12,5 Gy (9 - 15 Gy) and 20 Gy (12 - 28 Gy) for non-secretory and secretory adenomas, respectively. Tumor growth was controlled in 98% (41 in 42) of the cases and tumor shrinkage ocurred in 10% (4 in 42) of the cases. The 3-year actuarial rate of hormonal control and normalization were 62,4% and 37,6%, respectively, and the 5-year actuarial rate were 81,2% and 55,4%, respectively. The median latency period for hormonal control and normalization was, respectively, 15 and 18 months. On univariate analysis, there were no relationships between median dose or tumoral volume and hormonal control or normalization. There were no patients with visual deficit and 1 patient had hypopituitarism after RS.</p> <p>Conclusions</p> <p>RS is an effective and safe therapeutic option in the management of selected patients with pituitary adenomas. The short latency of the radiation response, the highly acceptable radiological and hormonal control and absence of complications at this early follow-up are consistent with literature.</p